Sentinel lymph node biopsy alone in the management of early cervical carcinoma. Issue 1 (16th June 2020)

• Record Type: Journal Article
• Authors: Devaja, Omer; Papadopoulos, Andreas John; Bharathan, Rasiah; Montalto, Stephen Attard; Coutts, Michael; Tan, Alex; Corrigan, Alexis; Perovic, Milica; Lalami, Seyedeh Zahra Rezaei
• Is Part Of: International journal of gynecological cancer. Volume 32:Issue 1(2022)
• Page Start: 15
• Page End: 20
• Publication Date: 2020-06-16
• Subjects: SLN and lympadenectomy -- cervix uteri -- cervical cancer; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2019-001082
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: Sentinel lymph node (SLN) biopsy aims to assess lymph node status with reduced surgical morbidity. The aim of the study was to determine the accuracy and safety of SLN biopsy in the management of early cervical carcinoma using a double technique (technetium-99m (Tc-99m) nanocolloid and methylene blue dye injection). Methods: This was a 10-year study from January 2009 to January 2019 that recruited 103 consecutive women undergoing surgery for early cervical carcinoma, FIGO 2009 stage IA1 (grade 3, and grade 2 with lymphovascular space invasion) to IB1 (<2 cm), at the West Kent Gynaecological Oncology Centre, Maidstone, UK. All patients were given the choice of pelvic node dissection and SLN mapping or SLN only. All patients elected to undergo SLN only. In total 97 patients had SLN mapping performed laparoscopically. We used the combined method (Tc-99m nanocolloid and/or methylene blue dye). All SLN routinely underwent ultrastaging. Results: At least one SLN was detected in all 103 patients, using at least one of the combined methods (Tc-99m nanocolloid or blue dye). Bilaterally SLN were removed in 85/103 women with an 83% bilateral detection rate. The median SLN count was 2.3 (range 1–6) nodes. Of 103 patients, 7 (6.7%) patients had lymph node involvement. There were no pelvic or para-aortic lymph node recurrences with a median follow-up of 53 (range 8–120) months. The specificity and negative predictive value of a negative SLN was 100%. None of our 103 patients reported lower extremity lymphedema. Conclusion: In carefully selected patients with early cervical carcinoma, SLN biopsy alone appears to be a safe method for lymph node assessment of women undergoing surgical staging. Ultrastaging is an essential part of histologic examination of SLN.